The federal contract IDV is a Federal Supply Schedule (FSS) contract awarded by the U.S. Department of Veterans Affairs (VA) to Helsinn Therapeutics (U.S.), Inc. (doing business as Helsinn Therapeutics US Inc.). The contract, valued at up to $33,573,490.00, covers the procurement of pharmaceutical products, specifically drugs, pharmaceuticals, and hematology-related products.
The prime contractor, Helsinn Therapeutics, is a for-profit manufacturer that provides the drug VALCHLOR, used to treat cutaneous T-cell lymphoma, to VA medical facilities. The contract is a multiple-award FSS with a period of performance from March 1, 2025, to February 28, 2030. It allows VA medical centers to efficiently procure VALCHLOR on an as-needed basis through delivery orders and a Blanket Purchase Agreement (BPA) with a potential value of $15,475,951.95. The contract does not utilize any set-aside provisions, and performance will be carried out within the United States by Helsinn Therapeutics as the prime contractor.
Generated 2/20/25, 9:02 AM